A bioactive compound isolated from Duku (*Lansium domesticum* Corr) fruit peels exhibits cytotoxicity against T47D cell line [version 1; peer review: 1 approved with reservations]

Khusnul Fadhilah¹, Subagus Wahyuono², Puji Astuti²

¹Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia
²Departement of Biology, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyaka, 55281, Indonesia

Abstract

**Background:** Breast cancer is a major health problem for women globally. Many attempts have been promoted to cure cancer by finding new anticancer medicines from natural resources. Despite the richness of biodiversity discovered, there are some natural resources that remain unexplored. Fruit peels of Duku (*Lansium domesticum* Corr.) are rich with compounds that may have the potential to be developed as anticancer drugs. This study aimed to isolate cytotoxic compounds from the fruit peels of *L. domesticum* and assess their cytotoxic nature against T47D cells.

**Methods:** Powdered peels were macerated with ethyl acetate and the filtrate was evaporated to give EtOAc extract A. Dried extract A was triturated with n-hexane to give n-hexane soluble fraction B and insoluble fraction C. The cytotoxic nature of these three samples were assessed using MTT assay using T47D cells and doxorubicin as a control.

**Results:** Fraction C that showed the smallest IC50 (25.56 ± 0.64μg/mL) value compared to extract A and fraction B. Fraction C was further fractionated by vacuum liquid chromatography to give 6 subfractions. Subfraction 2 showed a single compound based on thin layer chromatography, and this compound was identified as Lamesticumin A on the basis of its spectroscopic data. Lamesticumin A demonstrated cytotoxic activity against T47D cell lines with an IC50 value of 15.68 ± 0.30µg/mL.

**Conclusions:** Further research is needed to investigate the potential of the natural compound Lamesticumin A derived from *L. domesticum* fruit peel as an anticancer therapy.

Keywords

*Lansium domesticum* Corr., cytotoxic, T47D cell line, Lamesticumin A
Introduction
The most frequent cancer in women and that which causes the highest mortality is breast cancer. In Indonesia, it was reported that approximately 21% of cancer deaths among women were due to breast cancer. Therefore, new medicines to eradicate this type of cancer is required. Duku (Lansium domesticum Correa) widely grows in Indonesia. Traditionally, L. domesticum bark and seeds have been used to treat dysentery and fever. Based on previous studies, chloroform and methanol extracts of L. domesticum displayed cytotoxic activity on murine melanoma (B16F10) and colon cancer (HT29) cells. In addition, it has been shown that ethanol and ethyl acetate fractions of the peel have a deterrent activity on DNA damage in lymphblast cells induced by H2O2 exposure. Onocerinoid-type of triterpenoids have been isolated from twigs and leaves of L. domesticum, and these compounds showed antibacterial and antimutagenic activities. In this study, the cytotoxic effects of compound extracted from the peels of L. domesticum are assayed against breast cancer T47D cells.

Methods

Plant material
The fruits of L. domesticum were collected on March 2018 from Bantul, Yogyakarta (GPS : -7.871098, 110.394854) and identified at the Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Gadjah Mada.

Chemicals and equipment
Organic solvents (methanol, ethyl acetate, chloroform, n-hexane) used were pro analytical grades obtained from Merck. Silica gel F254, Silica gel PF254, (Merck), RPMI 1640, Fetal Bovine Serum, Penicillin-Streptomycin, Fungizon, Sodium bicarbonate (Gibco), HEPES (Invitrogen), Phosphate Buffered Saline, MTT (Sigma Aldrich cat. M5655), Doxorubicin (Sigma Aldrich). Infrared (KBr) spectrum was obtained from spectrophotometer (Shimadzu) using a method previously described by Ashokkumar and Ramaswamy. Ultraviolet spectrum (CHCl3) was obtained from UV spectrophotometer (Hitachi UH 5300). Sample (1 mg) were diluted in 1 mL CHCl3 and was run between 200–400 nm. Spectra of 1H- and 13C- NMR in CDCl3 solvent were measured using JEOL JNM-ECZ 500R/S1 at 500 MHz.

Extraction and fractionation
The peel was separated from the fruit, dried in oven 50°C for 24 hours and powdered using a blender. Powdered L. domesticum fruit peel (200 gr) was macerated with ethyl acetate (EtOAc; 2 L) overnight. This solution was filtrated (0.45μm) and the filtrate was evaporated to dryness with a rotary evaporator set at 50°C, to give dried EtOAc extract (A, 50.13 g). In order to separate the extract into non-polar and polar fractions, 6 gr of extract A was diluted 5 times using n-hexane (20 mL) to give soluble n-hexane fraction B (supernatant; 3.03 g) and insoluble n-hexane fraction C (residue; 2.83 g).

Fraction C was the most active among other fractions (see Results), and was therefore further fractionated using vacuum liquid chromatography as described by Mae Sri Hartati et al. In brief, using silica gel preparation grade (15 gr) as stationary phase this was eluted with n-hexane and increasing amounts of ethyl acetate. Six subfractions were obtained and subfraction 2 contained a major compound which appeared as white crystals (referred to as compound 1). Compound 1 was obtained as a single compound from subfraction 2, while the other subfractions still contained various compounds. Compound 1 (142.6 mg), had a melting point at 140–150°C (Figure 1). Compound 1 was identified using spectroscopy data such as ultraviolet (UV), infrared (IR), 13C-NMR and 1H-NMR (see section Chemicals and equipment).

Cytotoxic assay
The bioassay followed the methodology described by Bahuguna et al. with modifications. In brief, 100 μl T47D cells (in RPMI mediaFaculty of Medicine, Universitas Gadjah Mada) were placed in each well of a 96 well micro plates, resulting in 1 × 104 cells/well. The cells were incubated for 24 hours at 37°C in a CO2 incubator.

Extract A, fractions B and C and compound 1 (5mg) were dissolved in DMSO (50 μL). Serial concentrations of extract and fractions (50, 25, 12.5, 6.25, 3.125 μg/mL), compound 1 (25, 12.5, 6.25, 3.125 μg/mL) and doxorubicin (positive control; 0.5, 0.25, 0.125, 0.0625, 0.0312 μg/mL) were obtained. Cells were treated with the dose dependent samples and incubated for 24 hours at 37°C. The culture medium was removed by pipette, and MTT solution (100μL) was added to each well and incubated for 4 hours at 37°C. After incubation, stop solution (10% SDS, 100 μL) was added to each well and let stand at room temperature for 24 hours.

Absorbance was measured by microplate reader (Bio Rad) at 595 nm. positive control The data generated were used to plot a dose-response curve and IC50 of the samples was determined.

Statistical analysis
The IC50 values were analyzed by one-way ANOVA with statistical significance P < 0.05 using IBM SPSS ver.23.

Results

Compound 1 characterization
Identified as Lamesticumin A.

White crystal. IR (KBr) νmax cm⁻¹: 3074, 2960, 1712; UV (MeOH)λmax 236.5; 1H,13C-NMR: see Table 1; m/z 502; (Calculated for C31H31O5).

The infrared spectroscopy (KBr) spectrum of 1 showed a broad band at 3400–2800 cm⁻¹, which indicated the presence of –OH group, specifically –COOH due to intermolecular bonding. This data is supported by the appearance of –C=O at 1712 cm⁻¹. Compound 1 displayed UV absorption at 236.5 nm. The 13C-NMR spectrum (500 MHz, CDCl3) of compound 1 showed 30 carbons (Table 1). There were two down field carbon signals (δ, 147.6 and 148.1 ppm) identified as C=O signal carbons. Two characteristic terminals =CH2 signals (δ, 107.4 and 114.2 ppm) were observed, and this identity was confirmed by 2D (Het-Cor) NMR technique. Based on 13C-NMR...
Figure 1. Isolation process of cytotoxic compound 1 (subfraction 2) from *Lansium domesticum* fruit peels.

Table 1. 13C-NMR spectrum (500 MHz, CDCl3) of compound 1, Lamesticumin A.

<table>
<thead>
<tr>
<th>Position</th>
<th>¹H-NMR (J, Hz)</th>
<th>¹³C-NMR (ppm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.2 2H, triplet (7.0)</td>
<td>27.98</td>
</tr>
<tr>
<td>2</td>
<td>2.1 2H, triplet (6.8)</td>
<td>29.18</td>
</tr>
<tr>
<td>3</td>
<td>-   -</td>
<td>147.60</td>
</tr>
<tr>
<td>4</td>
<td>-   -</td>
<td>51.78</td>
</tr>
<tr>
<td>5</td>
<td>0.9 1H, triplet (7.1)</td>
<td>50.78</td>
</tr>
<tr>
<td>6</td>
<td>1.4 2H, multiplet</td>
<td>27.51</td>
</tr>
<tr>
<td>7</td>
<td>1.9 2H, triplet (6.8)</td>
<td>28.75</td>
</tr>
<tr>
<td>8</td>
<td>-   -</td>
<td>122.10</td>
</tr>
<tr>
<td>9</td>
<td>1.1 1H, triplet (7.0)</td>
<td>48.91</td>
</tr>
<tr>
<td>10</td>
<td>-   -</td>
<td>47.68</td>
</tr>
<tr>
<td>11</td>
<td>1.4 2H, multiplet</td>
<td>30.59</td>
</tr>
<tr>
<td>12</td>
<td>1.7 2H, multiplet</td>
<td>29.67</td>
</tr>
<tr>
<td>13</td>
<td>1.13 1H, triplet (7.0)</td>
<td>41.71</td>
</tr>
<tr>
<td>14</td>
<td>-   -</td>
<td>135.91</td>
</tr>
<tr>
<td>15</td>
<td>5.4 1H, triplet (6.8)</td>
<td>113.93</td>
</tr>
</tbody>
</table>

Table 2. ¹H-NMR (500 MHz, CDCl3) and ¹³C-NMR spectrum (500 MHz, CDCl3) of compound 1, Lamesticumin A.

<table>
<thead>
<tr>
<th>Position</th>
<th>¹H-NMR (J, Hz)</th>
<th>¹³C-NMR (ppm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>1.7 2H, dd (7.0, 6.8)</td>
<td>30.59</td>
</tr>
<tr>
<td>17</td>
<td>1.1 1H, triplet</td>
<td>31.81</td>
</tr>
<tr>
<td>18</td>
<td>-   -</td>
<td>38.85</td>
</tr>
<tr>
<td>19</td>
<td>1.2 2H, multiplet</td>
<td>32.09</td>
</tr>
<tr>
<td>20</td>
<td>2.1 2H, multiplet</td>
<td>33.15</td>
</tr>
<tr>
<td>21</td>
<td>-   -</td>
<td>148.10</td>
</tr>
<tr>
<td>22</td>
<td>-   -</td>
<td>147.20</td>
</tr>
<tr>
<td>23</td>
<td>1.7 3H, singlet</td>
<td>23.37</td>
</tr>
<tr>
<td>24</td>
<td>1.9 3H, singlet</td>
<td>23.76</td>
</tr>
<tr>
<td>25</td>
<td>0.8 3H, singlet</td>
<td>16.16</td>
</tr>
<tr>
<td>26</td>
<td>4.8 2H, dublet (9.1)</td>
<td>107.4</td>
</tr>
<tr>
<td>27</td>
<td>1.7 3H, Singlet</td>
<td>17.91</td>
</tr>
<tr>
<td>28</td>
<td>0.7 3H, singlet</td>
<td>14.37</td>
</tr>
<tr>
<td>29</td>
<td>4.6 2H, dublet (9.2)</td>
<td>114.23</td>
</tr>
<tr>
<td>30</td>
<td>1.6 3H, singlet</td>
<td>22.88</td>
</tr>
</tbody>
</table>

¹H- and ¹³C-NMR (CDCl3) spectra were obtained from JEOL JNM-ECZ 500R/S1, 500 MHz.
and ¹H-NMR data, compound 1 (Figure 2) was identified as Lamesticumin A (C₃₁H₅₀O₅, m/z, 502) which was previously isolated from L. domesticum twigs. Many triterpenoid compounds have been previously isolated from L. domesticum. Most of these compounds are UV inactive or have no strong UV absorbance because triterpenoid’s lack of a conjugated functional group. Lansiosida A and Dukunolida A has been isolated from n-hexane extract of L. domesticum fruit peel. Lamesticumin A is an onoceranoid-type triterpenoid, isolated previously from L. domesticum twigs, that has antibacterial activity against Staphylococcus aureus, Staphylococcus epidermidis, Micrococcus luteus, Bacillus subtilis, Micrococcus pyogenes and Bacillus cereus with minimum inhibitory concentration of <15 μg/ml. Another onoceranoid-type triterpenoid Lansium acid I-IX were isolated from L. domesticum leaves, which was reported to have antifungal activity.

Cytotoxicity of extract A, fractions B and C, and compound 1
The cytotoxicity of extract A, fractions B and C, compound 1 and doxorubicin (positive control) is shown in Table 2. Fraction C was the most cytotoxic (IC₅₀ 25.57 μg/mL) compared with extract A (29.41 μg/mL) and fraction B (43.51 μg/mL). The IC₅₀ of the isolated compound from fraction C, compound 1/Lamesticumin A was 15.68 μg/mL. All samples inhibited T47D cell growth in a dose dependent behavior (Figure 3).

Discussion
In this study, the cytotoxic activity of Lamesticumin A, derived from the peel of L. domesticum, was demonstrated in the T47D cell line with IC₅₀ 15.68 (μg/ml). The T47D cell line is an epithelial breast cancer cell subtype luminal A cell line that express estrogen and progesterone receptors. Based on National Cancer Institute guidelines, a natural compound has potent anticancer activity if it has IC₅₀ <4 μg/ml or 10 μM. Based on several in vitro tests, some terpenoid compounds had anticancer activity. Sesquiterpene lactone compounds are known to inhibit NF-kB, thereby inducing apoptosis. Celastrol has anticancer properties by regulating various transcription factors, angiogenesis processes, cell cycle arrest and induction of apoptosis. Betulinic acid can induce apoptosis in HT-29 colon cancer cells and acts as a chemosensitizer for chemotherapeutic agents in wildtype adenocarcinoma cancer cells (SNU-C5/WT).

Table 2. IC₅₀ values of extract, fractions and isolated compound 1 against T47D breast cancer cell line.

<table>
<thead>
<tr>
<th></th>
<th>IC₅₀ (μg/ml), mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extract A</td>
<td>29.41 ± 0.67</td>
</tr>
<tr>
<td>Fraction B</td>
<td>43.51 ± 1.77</td>
</tr>
<tr>
<td>Fraction C</td>
<td>25.56 ± 0.64</td>
</tr>
<tr>
<td>Lamesticumin A</td>
<td>15.68 ± 0.30</td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>0.18 ± 0.01</td>
</tr>
</tbody>
</table>

Figure 2. Isolated compound 1, Lamesticumin A.
Figure 3. T47D breast cancer cell line viability after treatments with extracts from *Lansium domesticum* fruit peels. Error bars shows standard deviation.

Clematangoticosides D and F from *Clematis tangutica* are known to have cytotoxic activity against human gastric cancer cell line (SGC-7901) with IC\textsubscript{50} 24.22 and 21.35 μM, respectively\textsuperscript{18}. Cycloartane-type and oleanane-type triterpenoids from *Ligularia przewalskii* show cytotoxicity in Hela, HEPG2, SGC7901, MDA231, HL-60, and Lewis cell lines with IC\textsubscript{50} 8.40–24.39 μM\textsuperscript{19}.

It has been reported that natural compounds combined with low doses of antineoplastics can increase effectiveness and reduce toxic effects\textsuperscript{20}. Betulinic acid can induce apoptosis when combined with 5-fluorouracil, irinotecan and oxaliplatin\textsuperscript{4}. Ursolic acid (UA), a pentacyclic triterpenoid, is known to have anticancer activity through interfering with multiple signaling pathways. Furthermore, UA has been shown to act as a chemosensitizing agent to increase the effect of conventional anticancer drugs\textsuperscript{21}, and to increase the effect of doxorubicin by increasing the cellular amount of the drug in the MCF cell line\textsuperscript{22}. Further study is needed to investigate the possibility of Lamesticumin A to be combined with doxorubicin for its potential to have synergistic effect.

Conclusions
Extract, fractions and Lamesticumin A derived from the peel of *L. domesticum* showed cytotoxic activity against the T47D breast cancer cell line. Further research is needed to investigate the potential of the natural compound Lamesticumin A derived from *L. domesticum* fruit peel as an anticancer therapy.

Data availability
Underlying data
Zenodo: A bioactive compound isolated from Duku (*Lansium domesticum* Corr) fruit peels exhibits cytotoxicity against T47D cell line, [http://doi.org/10.5281/zenodo.3539670]\textsuperscript{23}.

This project contains the following underlying data:
- UV, infrared, \textsuperscript{13}C-NMR and \textsuperscript{1}H-NMR spectra of compound 1.
- Cell viability and IC\textsubscript{50} values of extract A, fractions B and C, compound 1 and doxorubicin in T47D cell line.

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
Components of Active Fractions from Lansium domesticum Corr. Fruit. 
Nutrients. 2015; 7(8): 6852–73. 
PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text

6. Matsumoto T, Kitagawa T, Teo S, et al.: Structures and Antimutagenic Effects of 
Onoceranoid-Type Triterpenoids from the Leaves of Lansium domesticum. 
PubMed Abstract | Publisher Full Text

Reference Source

Reference Source

Reference Source

PubMed Abstract | Publisher Full Text

Reference Source

Reference Source

tetranortriterpenoid with a new carbon skeleton from lansium domesticum. 
Publisher Full Text

novel triterpene glycoside with amino-sugar from lansium domesticum. 
Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

Publisher Full Text

PubMed Abstract | Publisher Full Text

Publisher Full Text

PubMed Abstract | Publisher Full Text

Major points:
The extracts and purified bioactive compound, Lamesticumin A, from this plant, is not novel, since it was isolated from the twigs from this same herb in the previous report. The anticancer activity of the active compound is not promising since it is more than 4 microgram/mL or 10 micromolar, the level of which the National Cancer Institution defines is 4 microgram/mL or less than this. However, the authors discussed of using this compound as a chemosensitizing agent, which various steps still are needed before launching it as a therapeutic anti-cancer drug. The authors should explore the cytotoxic effects of the extracts, EtOAc extract (A), N-hexane fraction (B), N-hexane insoluble fraction (C) and compound 1 (Lamesticumin A) on normal cells.

In Figure 3, the percent cell viabilities of EtOAc extract (A), N-hexane fraction (B), N-hexane insoluble fraction (C) and compound 1 (Lamesticumin A) should be presented with the statistical significance by using asterisks, such as *p<0.05, **p<0.01, and so on, above the dots.

Minor points:
The sources of chemicals and instruments should indicate the city and country that they are produced from. Sometimes the authors used gr and sometimes g, it should be consistent with each other. In subtopic “Cytotoxic assay”, in 3rd – 4th lines, the authors should rewrite the sentences. There are many grammar and various typological errors, such as the number of g it should be 43.4 rather than 43,4, etc. For the previous findings, the sentences should be in present tense, but for the authors’ research data in the Results and Discussion parts, the sentences would be in past tense. For MDA231, it should be MDA-MB-231 breast cancer cells. For MCF, it should be clarified as MCF-7 or not? In Ref. No. 12, there is no information of company, city, country of publication, is it a book? Ref. No. 21, the name of journal is full name, whereas others are in abbreviated forms. It should be consistent with each other.

References
Abstract | Publisher Full Text

Is the work clearly and accurately presented and does it cite the current literature?  
Yes

Is the study design appropriate and is the work technically sound?  
Yes

Are sufficient details of methods and analysis provided to allow replication by others?  
Yes

If applicable, is the statistical analysis and its interpretation appropriate?  
Partly

Are all the source data underlying the results available to ensure full reproducibility?  
Yes

Are the conclusions drawn adequately supported by the results?  
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Programmed cell death, Natural products, Antioxidants, Cancer.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

The benefits of publishing with F1000Research:

• Your article is published within days, with no editorial bias
• You can publish traditional articles, null/negative results, case reports, data notes and more
• The peer review process is transparent and collaborative
• Your article is indexed in PubMed after passing peer review
• Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com